Trial Tests Whether Stopping Immunotherapy Early Harms NSCLC Patients Who Respond
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
Summary
This Phase 2 trial from Institut Bergonié explored a pressing clinical question in lung cancer care: once a patient responds to immune checkpoint inhibitor therapy within 6 to 12 months, is it safe to stop treatment? Continuing immunotherapy indefinitely carries costs, side effects, and quality-of-life burdens, yet stopping too early risks disease relapse. The study randomized NSCLC patients who achieved a meaningful response to either continue or discontinue their PD-1 or PD-L1 blocking therapy. Unfortunately, the trial was terminated early with only 8 participants enrolled, far below the target needed for meaningful statistical conclusions. While no efficacy data are available, the research question remains critically important for oncology practice and patient wellbeing. Larger, better-powered studies are urgently needed to answer this unresolved question.
Detailed Summary
One of the most pressing unanswered questions in modern oncology is how long patients with non-small cell lung cancer should continue immune checkpoint inhibitor therapy once they achieve a clinical response. Indefinite treatment carries significant financial costs and cumulative immune-related adverse effects, while premature discontinuation risks disease progression. This trial sought to address that dilemma directly.
The study was a non-comparative, multicentric, randomized Phase 2 trial enrolling NSCLC patients who had experienced a measurable response between 6 and 12 months after starting PD-1 or PD-L1 blockade therapy. Participants were randomized to either continue their immunotherapy or discontinue it, with long-term outcomes tracked through a planned completion date of February 2026. The trial was sponsored by Institut Bergonié, a French comprehensive cancer center.
Unfortunately, the trial was terminated before generating meaningful data, with only 8 participants enrolled. No efficacy or safety outcome data are available in the public record. The reasons for termination are not specified in the available abstract, but early termination of oncology trials is commonly attributed to slow accrual, funding constraints, or protocol amendments.
Despite the premature closure, the underlying scientific question is of substantial clinical importance. Physicians managing NSCLC patients on checkpoint inhibitors frequently face pressure from patients and payers to define an endpoint for treatment. Tumor microenvironment analyses were included in the trial design, suggesting an ambition to identify biomarkers predictive of durable response after discontinuation.
The failure to complete this trial underscores the difficulty of conducting randomized discontinuation studies in oncology. Patients and clinicians are often reluctant to accept randomization to stopping a working therapy. Future efforts may need adaptive designs, stronger institutional partnerships, or registry-based approaches to resolve this clinically critical question definitively.
Key Findings
- Trial was terminated early with only 8 of its intended participants enrolled, yielding no efficacy conclusions.
- Study targeted NSCLC patients who responded to checkpoint inhibitors within 6-12 months of starting therapy.
- Patients were randomized to continue or discontinue PD-1/PD-L1 blockade after confirmed response.
- Tumor microenvironment analysis was embedded in the design to identify biomarkers for durable response.
- The core clinical question — optimal immunotherapy duration — remains unanswered and urgently relevant.
Methodology
Non-comparative multicentric randomized Phase 2 design enrolling NSCLC responders at 6–12 months post-ICI initiation. Participants were randomized to ICI continuation versus discontinuation, with planned follow-up through February 2026. The trial was terminated early with only 8 participants enrolled, rendering the design underpowered for any statistical analysis.
Study Limitations
The trial was terminated with only 8 enrollees, making any clinical or statistical conclusions impossible. This summary is based on the abstract only; full protocol details, reasons for termination, and any interim data are unavailable. The non-comparative design and small intended sample size would have limited generalizability even if completed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.